Veteran Pharmaceutical Executive Joins AerovectRx Corp. Board.ATLANTA -- AerovectRx Corporation, developer of new unit dose aerosol drug delivery technology, today announced that Jonathan Mow has joined the company's board of directors. Mr. Mow has extensive experience in pharmaceutical marketing and business development, with his last two companies focusing on the development and commercialization of aerosol drugs. "I am very please that Jonathan has joined our board, bringing his wealth of aerosol drug industry knowledge," said Matthew H.J. Kim, J.D., founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of AerovectRx. "He has been an integral part of creating and growing two highly successful aerosol therapy companies that together were acquired for more than one billion dollars." "The AerovectRx team has developed a technology platform that represents a tremendous opportunity in the growing aerosol delivery industry," said Mr. Mow. "I believe that the unique AerovectRx platform technology will serve an important need that is not currently being addressed in the aerosol market - disposable, unit-dose cartridges that can be used to efficiently deliver high-value medications." As co-founder of Corus Pharma, Mr. Mow was an integral member of the management team that positioned the company's aerosol drug pipeline to be acquired for approximately $420 million by Gilead Sciences in 2006. He also was an executive with the respiratory therapeutic company PathoGenesis Corporation which was acquired by Chiron for approximately $700 million in 2000. Mr. Mow previously worked in various strategic planning and marketing positions at Bristol-Myers Squibb, Lederle/Wyeth International and Syntex Laboratories. About AerovectRx -- AerovectRx Corporation is an aerosol therapeutic company providing effective and dosage-controlled drug delivery using the respiratory system respiratory system: see respiration. respiratory system Organ system involved in respiration. In humans, the diaphragm and, to a lesser extent, the muscles between the ribs generate a pumping action, moving air in and out of the lungs through a as the gateway for better health. Products under development by AerovectRx are designed to deliver a wide variety of therapies through multiple-use mass immunization immunization: see immunity; vaccination. as well as personal-use nebulizers. Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. , pulmonary hypertension Pulmonary Hypertension Definition Pulmonary hypertension is a rare lung disorder characterized by increased pressure in the pulmonary artery. The pulmonary artery carries oxygen-poor blood from the lower chamber on the right side of the heart (right , chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. (COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) ), diabetes, pain management, and for delivery of vaccines and anti-viral drugs. For more information, visit www.aerovectrx.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion